The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells

Journal of Clinical Investigation

Volumn 119, Issue 12, 2009, Pages 3626-3636

  Song, Li Bing ^a   Li, Jun ^b   Liao, Wen Ting ^a   Feng, Yan ^a   Yu, Chun Ping ^a   Hu, Li Juan ^a   Kong, Qing Li ^a   Xu, Li Hua ^a   Zhang, Xing ^a   Liu, Wan Li ^a   Li, Man Zhi ^a   Zhang, Ling ^a   Kang, Tie Bang ^a   Fu, Li Wu ^a   Huang, Wen Lin ^a   Xia, Yun Fei ^a   Tsao, Sai Wah ^c   Li, Mengfeng ^b   Band, Vimla ^d   Band, Hamid ^d   Shi, Qing Hua ^e   Zeng, Yi Xin ^a   Zeng, Mu Sheng ^a   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN;

ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIUM CELL; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; MESENCHYME; MOLECULAR MECHANICS; NASOPHARYNX; NASOPHARYNX CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION; TRANSCRIPTION TERMINATION; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CADHERINS; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL CELLS; GENE SILENCING; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MESODERM; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 72849130207     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39374     Document Type: Article

References (78)

1. Pirrotta, V. 1998. Polycombing the genome: PcG, trxG, and chromatin silencing. Cell. 93:333-336. (Pubitemid 28232078)
2. Jacobs, J.J., and van Lohuizen, M. 2002. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim. Biophys. Acta. 1602:151-161.
3. Raaphorst, F.M. 2005. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum. Mol. Genet. 14:R93-R100.
4. Kondo, Y., et al. 2008. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40:741-750. (Pubitemid 351748874)
5. Bachmann, I.M., et al. 2006. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24:268-273.
6. Kleer, C.G., et al. 2003. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 100:11606-11611.
7. Raman, J.D., et al. 2005. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 11:8570-8576. (Pubitemid 43005902)
8. Sellers, W.R., and Loda, M. 2002. The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer? Cancer Cell. 2:349-350. (Pubitemid 41039099)
9. Varambally, S., et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624-629.
10. Wang, S., Robertson, G.P., and Zhu, J. 2004. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene. 343:69-78. (Pubitemid 39551030)
11. Haupt, Y., Alexander, W.S., Barri, G., Klinken, S.P., and Adams, J.M. 1991. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 65:753-763. (Pubitemid 121001307)
12. van Lohuizen, M., et al. 1991. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 65:737-752.
13. Liu, S., et al. 2006. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66:6063-6071.
14. Mihic-Probst, D., et al. 2007. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int. J. Cancer. 121:1764-1770. (Pubitemid 47417295)
15. Bea, S., et al. 2001. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 61:2409-2412. (Pubitemid 32685815)
16. Kim, J.H., et al. 2004. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 13:383-388.
17. Ringrose, L., and Paro, R. 2004. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu. Rev. Genet. 38:413-443. (Pubitemid 40013734)
18. van Kemenade, F.J., et al. 2001. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 97:3896-3901.
19. Qin, Z.K., et al. 2009. Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer. 9:61.
20. Song, L.B., et al. 2006. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 66:6225-6232.
21. Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 397:164-168. (Pubitemid 29050921)
22. Bruggeman, S.W., et al. 2007. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 12:328-341.
23. Lee, T.I., et al. 2006. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 125:301-313. (Pubitemid 44313811)
24. Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H., and Helin, K. 2006. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20:1123-1136.
25. Boyer, L.A., et al. 2006. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 441:349-353.
26. Larue, L., and Bellacosa, A. 2005. Epithelialmesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 24:7443-7454. (Pubitemid 41637984)
27. Christofori, G. 2006. New signals from the invasive front. Nature. 441:444-450.
28. Thiery, J.P., and Sleeman, J.P. 2006. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7:131-142.
29. Huber, M.A., Kraut, N., and Beug, H. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17:548-558. (Pubitemid 41267170)
30. Cano, A., et al. 2000. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2:76-83. (Pubitemid 30785917)
31. Nieto, M.A. 2002. The snail superfamily of zincfinger transcription factors. Nat. Rev. Mol. Cell Biol. 3:155-166. (Pubitemid 37237138)
32. Chua, H.L., et al. 2007. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene. 26:711-724.
33. Eger, A., et al. 2005. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 24:2375-2385.
34. Yang, J., et al. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927-939.
35. Perez-Moreno, M.A., et al. 2001. A new role for E12/ E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J. Biol. Chem. 276:27424-27431. (Pubitemid 37410659)
36. Blumenberg, M., et al. 2007. Chromatin structure regulation in transforming growth factor-beta-directed epithelial-mesenchymal transition. Cells Tissues Organs. 185:162-174. (Pubitemid 46956857)
37. Cao, Q., et al. 2008. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 27:7274-7284.
38. Guo, W.J., et al. 2007. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 67:5083-5089.
39. Bakin, A.V., Tomlinson, A.K., Bhowmick, N.A., Moses, H.L., and Arteaga, C.L. 2000. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275:36803-36810.
40. Grille, S.J., et al. 2003. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63:2172-2178.
41. Julien, S., et al. 2007. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 26:7445-7456.
42. Wang, H., et al. 2007. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 67:2922-2926. (Pubitemid 46724825)
43. Bachelder, R.E., Yoon, S.O., Franci, C., de Herreros, A.G., and Mercurio, A.M. 2005. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelialmesenchymal transition. J. Cell Biol. 168:29-33. (Pubitemid 40111054)
44. Zhou, B.P., et al. 2004. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6:931-940.
45. Herranz, N., et al. 2008. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol. Cell. Biol. 28:4772-4781.
46. Blanco-Aparicio, C., Renner, O., Leal, J.F., and Carnero, A. 2007. PTEN, more than the AKT pathway. Carcinogenesis. 28:1379-1386. (Pubitemid 47243536)
47. Fischle, W., et al. 2003. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev. 17:1870-1881. (Pubitemid 36944564)
48. Fandi, A., Altun, M., Azli, N., Armand, J.P., and Cvitkovic, E. 1994. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin. Oncol. 21:382-397. (Pubitemid 24191598)
49. Vonlanthen, S., et al. 2001. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer. 84:1372-1376. (Pubitemid 32522106)
50. Glinsky, G.V., Berezovska, O., and Glinskii, A.B. 2005. Microarray analysis identifies a death-fromcancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115:1503-1521. (Pubitemid 40814659)
51. Lee, J.M., Dedhar, S., Kalluri, R., and Thompson, E.W. 2006. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172:973-981.
52. Thiery, J.P. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer. 2:442-454.
53. Comijn, J., et al. 2001. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell. 7:1267-1278.
54. Wu, X., et al. 2006. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 66:9527-9534. (Pubitemid 44623651)
55. Datta, S., et al. 2007. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res. 67:10286-10295. (Pubitemid 350070802)
56. Grunert, S., Jechlinger, M., and Beug, H. 2003. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 4:657-665. (Pubitemid 36934968)
57. Waerner, T., et al. 2006. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell. 10:227-239.
58. Mani, S.A., et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704-715.
59. Lessard, J., and Sauvageau, G. 2003. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 423:255-260. (Pubitemid 40852690)
60. Park, I.K., et al. 2003. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 423:302-305.
61. Molofsky, A.V., et al. 2003. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 425:962-967.
62. Su, I.H., et al. 2005. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell. 121:425-436.
63. Yu, J., et al. 2007. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 12:419-431.
64. Altomare, D.A., and Testa, J.R. 2005. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455-7464. (Pubitemid 41637985)
65. Li, J., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1943-1947. (Pubitemid 27148818)
66. Vivanco, I., and Sawyers, C.L. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:489-501. (Pubitemid 37328931)
67. Leslie, N.R., Yang, X., Downes, C.P., and Weijer, C.J. 2007. PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr. Biol. 17:115-125. (Pubitemid 46107842)
68. Escriva, M., et al. 2008. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol. Cell. Biol. 28:1528-1540.
69. Squazzo, S.L., et al. 2006. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 16:890-900.
70. Suzuki, A., et al. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8:1169-1178.
71. Haupt, Y., Bath, M.L., Harris, A.W., and Adams, J.M. 1993. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 8:3161-3164. (Pubitemid 23312924)
72. Molofsky, A.V., He, S., Bydon, M., Morrison, S.J., and Pardal, R. 2005. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 19:1432-1437. (Pubitemid 41003009)
73. Groszer, M., et al. 2001. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science. 294:2186-2189. (Pubitemid 33150679)
74. Yilmaz, O.H., et al. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemiainitiating cells. Nature. 441:475-482. (Pubitemid 44050144)
75. Guo, W.J., Datta, S., Band, V., and Dimri, G.P. 2007. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol. Biol. Cell. 18:536-546. (Pubitemid 46213222)
76. Dimri, G.P., Itahana, K., Acosta, M., and Campisi, J. 2000. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol. Cell. Biol. 20:273-285. (Pubitemid 30002569)
77. Quintana, E., et al. 2008. Efficient tumour formation by single human melanoma cells. Nature. 456:593-598.
78. Zeng, M., et al. 2002. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J. Biol. Chem. 277:45611-45618. (Pubitemid 36159172)